Efficacy and safety of immunotherapy rechallenge in second-line treatment after failure of first-line immune checkpoint inhibitors combined with chemotherapy in advanced gastric cancer: a retrospective study

For AGC patients who progressed after first-line ICI combined chemotherapy, immunotherapy rechallenge confers significant survival benefits compared to chemotherapy. Immunotherapy rechallenge is more effective in patients with high PD-L1 expression, suggesting its potential clinical application value as second-line treatment regimen.